Daily Endocrinology Research Analysis
Three studies span the translational spectrum in endocrinology: a comprehensive systematic review maps the rapidly expanding pipeline of anti-obesity pharmacotherapies; a mechanistic study identifies CYP7B1 as a protective hepatic enzyme attenuating early MASLD under a Western diet; and a meta-analysis confirms teprotumumab’s efficacy in thyroid eye disease while clarifying safety signals.
Summary
Three studies span the translational spectrum in endocrinology: a comprehensive systematic review maps the rapidly expanding pipeline of anti-obesity pharmacotherapies; a mechanistic study identifies CYP7B1 as a protective hepatic enzyme attenuating early MASLD under a Western diet; and a meta-analysis confirms teprotumumab’s efficacy in thyroid eye disease while clarifying safety signals.
Research Themes
- Emerging anti-obesity pharmacotherapy and incretin-based combinations
- Oxysterol metabolism (CYP7B1) in MASLD pathogenesis and therapy
- IGF-1R inhibition (teprotumumab) in thyroid eye disease: efficacy and safety
Selected Articles
1. Emerging pharmacotherapies for obesity: A systematic review.
This systematic review catalogs 53 phase 2/3 trials of emerging anti-obesity agents, highlighting the dominance of incretin-based therapies and reporting phase 2 mean weight loss ranging from 7.4% to 24.2%. Oral semaglutide 50 mg is the only agent to complete phase 3 to date, and multiple GLP-1-based combinations are in ongoing phase 3 trials. Evidence gaps include long-term safety, mortality, cardio-renal outcomes, and data in underrepresented populations.
Impact: Obesity is a central driver of endocrine-metabolic disease, and this review synthesizes the most complete, timely map of late-stage pharmacotherapy options with direct clinical and research implications.
Clinical Implications: Clinicians should anticipate broader availability of potent incretin-based regimens and prepare for individualized selection, monitoring of GI and metabolic AEs, and long-term weight maintenance strategies, while recognizing evidence gaps in mortality and cardio-renal endpoints.
Key Findings
- Identified 53 phase 2/3 trials with 36 emerging anti-obesity agents or combinations; 4 trials were withdrawn/terminated.
- Incretin-based therapies dominate; completed phase 2 programs report mean weight loss ranging 7.4% to 24.2%.
- Oral semaglutide 50 mg is the only agent with completed phase 3; 14 phase 3 trials (e.g., CagriSema, mazdutide, retatrutide) are ongoing.
- Critical evidence gaps include long-term safety, mortality, cardio-renal-metabolic outcomes, cost-effectiveness, and equity/availability.
Methodological Strengths
- Comprehensive multi-database search (Medline, Embase, ClinicalTrials.gov) spanning 2012–2024
- Focus on late-phase (phase 2/3) interventional trials with mechanistic categorization of agents
Limitations
- Heterogeneity across trials limits quantitative synthesis and between-drug comparisons
- Limited long-term outcomes (mortality, cardio-renal events) and underrepresentation of key subpopulations
Future Directions: Prospective head-to-head trials, long-term extension studies capturing cardio-renal-mortality endpoints, pragmatic effectiveness/cost studies, and inclusion of underrepresented populations.
The history of antiobesity pharmacotherapies is marked by disappointments, often entangled with societal pressure promoting weight loss and the prevailing conviction that excess body weight signifies a lack of willpower. However, categories of emerging pharmacotherapies generate hope to reduce obesity rates. This systematic review of phase 2 and phase 3 trials in adults with overweight/obesity investigates the effect of novel weight loss pharmacotherapies, compared to placebo/control or US Food and Drug Administration-approved weight loss medication, through searching Medline, Embase, and ClinicalTrials.gov (2012-2024). We identified 53 phase 3 and phase 2 trials, with 36 emerging antiobesity drugs or combinations thereof and 4 withdrawn or terminated trials. Oral semaglutide 50 mg is the only medication that has completed a phase 3 trial.
2. Liver specific transgenic expression of CYP7B1 attenuates early western diet-induced MASLD progression.
CYP7B1, a key oxysterol 7α-hydroxylase, is consistently downregulated in MASLD across mouse models and human cohorts, leading to accumulation of bioactive oxysterols. Liver-specific CYP7B1 overexpression attenuated early MASLD progression under Western diet challenge, supporting oxysterol detoxification as a therapeutic strategy.
Impact: Identifies a modifiable metabolic pathway (CYP7B1–oxysterol axis) with translational potential for MASLD, a prevalent endocrine-metabolic liver disease lacking approved disease-modifying drugs.
Clinical Implications: Although preclinical, findings support therapeutic development targeting oxysterol metabolism (e.g., enhancing CYP7B1 activity) to slow early MASLD. Biomarker strategies might include profiling 26HC/25HC to identify candidates for pathway modulation.
Key Findings
- CYP7B1 expression is consistently suppressed in MASLD across multiple mouse models and human cohorts.
- Suppression of CYP7B1 leads to accumulation of bioactive oxysterols (e.g., 26HC, 25HC).
- Liver-specific transgenic overexpression of CYP7B1 attenuates early Western diet–induced MASLD progression in mice.
Methodological Strengths
- Transgenic, organ-specific manipulation enabling causal inference on pathway function
- Cross-species consistency (mouse models and human cohort observations) for target validation
Limitations
- Preclinical animal study; human efficacy and safety remain untested
- Focus on early MASLD; effects on advanced fibrosis or NASH resolution are unknown
Future Directions: Develop small molecules/biologics to enhance CYP7B1 activity or reduce pathologic oxysterols; validate oxysterol biomarkers; and translate to early-phase human trials with histologic and metabolic endpoints.
Effect of liver specific oxysterol 7α-hydroxylase (CYP7B1) overexpression on the Western diet (WD)-induced metabolic dysfunction-associated steatotic liver disease (MASLD) progression was studied in mice. Among various hepatic genes impacted during MASLD development, CYP7B1 is consistently suppressed in multiple MASLD mouse models and in human MASLD cohorts. CYP7B1 enzyme suppression leads to accumulations of bioactive oxysterols such as (25R)26-hydroxycholesterol (26HC) and 25-hydroxycholesterol (25HC). We challenged liver specific CYP7B1 transgenic (CYP7B1
3. Efficacy and Safety of Teprotumumab in Thyroid Eye Disease: A Systematic Review and Meta-Analysis.
Across 4 RCTs (n=210 teprotumumab; n=193 controls) and 6 observational studies, teprotumumab significantly improved proptosis response, diplopia, and CAS versus placebo, with a large reduction in proptosis. Adverse events and serious adverse events were more frequent with teprotumumab, underscoring the need for careful monitoring and risk-benefit discussions.
Impact: Provides a high-level synthesis confirming robust clinical benefits of IGF-1R inhibition in TED while quantifying safety risks, informing first-line therapy considerations.
Clinical Implications: Teprotumumab can be considered a first-line option for active moderate-to-severe TED, with counseling on AEs (e.g., hyperglycemia, hearing changes) and structured monitoring; shared decision-making is essential, especially in patients with comorbid diabetes or otologic risk.
Key Findings
- In RCTs (n=210 teprotumumab; n=193 controls), teprotumumab improved proptosis response (RR 4.18), diplopia regression (RR 2.29), and CAS (RR 3.09) versus placebo.
- Marked reduction in proptosis was observed (standardized mean difference −8.38).
- Adverse events and serious adverse events were more frequent with teprotumumab; observational studies showed AE incidence ~0.78 and serious AEs ~0.31.
Methodological Strengths
- Includes randomized controlled trials complemented by real-world observational data
- Comprehensive multi-database search and consistent direction of effects across endpoints
Limitations
- Heterogeneity in prior treatments, disease activity, and dosing schedules across included studies
- Safety follow-up durations are limited; long-term relapse and AE trajectories remain uncertain
Future Directions: Long-term safety/effectiveness registries, head-to-head trials versus other immunomodulators, and strategies to mitigate AEs (e.g., metabolic monitoring protocols).
OBJECTIVE: Teprotumumab was approved by the US Food and Drug Administration (FDA) for treating Graves' orbitopathy in adults on January 21, 2020. This study evaluates its efficacy and safety in treating thyroid eye disease (TED). METHODS: We reviewed studies on teprotumumab for TED treatment from PubMed, Web of Science, EMBASE, Cochrane library, and Clinical trials. gov up to January 1, 2024. Outcomes included proptosis response, diplopia, Clinical Activity Score (CAS) score, and adverse events (AEs). RESULTS: Our analysis included 10 studies, 4 randomized controlled trials, and 6 observational studies. The randomized controlled trials involved 210 teprotumumab patients and 193 controls. Teprotumumab significantly improved proptosis response (relative risk [RR] 4.18, 2.72-6.43), diplopia regression (RR 2.29, 1.54-3.41), and CAS score (RR 3.09, 1.98-4.80) compared to placebo.